Lundbeck joins Global Alzheimer’s Platform

Lundbeck has joined the Global Alzheimer's Platform (GAP), an innovative worldwide Alzheimer's disease research initiative.

The publicly-funded project involves collaboration among pharmaceutical companies, academic institutions and nonprofit patient advocacy organisations, with the aim of reducing the time and costs of Alzheimer's clinical trials.

It also seeks to develop an infrastructure that promotes innovation and assure international partnership on Alzheimer's disease treatments. Lundbeck has sought membership to reflect its focus and commitment in the field of brain disorders.

Currently, the company has three Alzheimer's compounds  in development, including two phase III investigational therapies to address symptoms of the disease and a phase I vaccine candidate to potentially slow disease progression.

Dr Gary Tong, US therapeutic area head for dementia clinical research at Lundbeck, said: "We're looking forward to working with GAP to improve the clinical trial process in hopes of accelerating the availability of new therapies for the Alzheimer's disease community."

The firm employs more than 6,000 people worldwide, with products are registered in more than 100 countries.